• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,140
109
75
71
68

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 120
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

1,036
1,235
1,968
2,993

PUBLISHED

21
204
653
2,993

PRODUCT TYPE

2,420
494
69
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014 Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014

The Alpha6 Beta4 Integrin signaling pathway activates the PI 3-kinase/Akt, MAPK/NFkB and SMAD signaling modules. There are today 245 companies plus partners developing 385 Alpha6Beta4 integrin pathway...

July 2014
FROM
Pancreatic Cancer Drug Pipeline Update 2014 Pancreatic Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Pancreatic Cancer Drug Pipeline Update 2014

There are today 272 companies plus partners developing 328 drugs targeting pancreatic cancer in development. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the...

July 2014
FROM
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

Activation of the B cell receptor involves phosphorylation of the cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) present in Ig alpha and beta. This leads to activation of several...

July 2014
FROM
TSH Signaling Pathway in Oncology Drug Pipeline Update 2014 TSH Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TSH Signaling Pathway in Oncology Drug Pipeline Update 2014

Human thyroid stimulating hormone (TSH) exerts its action through various signaling cascades such as cAMP cascade and the phospholipase C beta-mediated inositol phosphate generation. Further, it will...

July 2014
FROM
Cancer Vaccines Drug Pipeline Update 2014 Cancer Vaccines Drug Pipeline Update 2014 - Product Thumbnail Image

Cancer Vaccines Drug Pipeline Update 2014

Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit...

July 2014
FROM
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014

IL-7 signaling pathway mainly activates the JAK/STAT signaling module. There are today 66 companies plus partners developing 72 IL-7 pathway targeting drugs in 299 developmental projects in cancer....

July 2014
FROM
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014 RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014

Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies. There are today...

July 2014
Prostate Cancer Drug Pipeline Update 2014 Prostate Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Prostate Cancer Drug Pipeline Update 2014

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various...

July 2014
FROM
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014 Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014

Inflammatory immune response requires the recruitment of leukocytes to the site of inflammation upon foreign insult. Chemokines are small chemoattractant peptides that provide directional cues for the...

July 2014
FROM
Adherens Junction Targeting in Oncology Drug Pipeline Update 2014 Adherens Junction Targeting in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Adherens Junction Targeting in Oncology Drug Pipeline Update 2014

Cell-cell adherens junctions, the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. There...

July 2014
FROM
Lymphoma Drug Pipeline Update 2014 Lymphoma Drug Pipeline Update 2014 - Product Thumbnail Image

Lymphoma Drug Pipeline Update 2014

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today 249 companies plus partners developing 381 lymphoma drugs in 606 developmental projects in cancer....

July 2014
FROM
Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2014 Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2014

Natural killer (NK) cells are lymphocytes of the innate immune system that are involved in early defenses against both allogeneic (nonself) cells and autologous cells undergoing various forms of stress,...

July 2014
FROM
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014 VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014

There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic and pathologic...

July 2014
FROM
Renal Cancer Drug Pipeline Update 2014 Renal Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Renal Cancer Drug Pipeline Update 2014

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being...

July 2014
FROM
Neuroendocrine Tumors Drug Pipeline Update 2014 Neuroendocrine Tumors Drug Pipeline Update 2014 - Product Thumbnail Image

Neuroendocrine Tumors Drug Pipeline Update 2014

There are today 78 companies plus partners developing 86 neuroendocrine tumor drugs in 125 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount...

July 2014
FROM
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014 Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just...

July 2014
FROM
Cytokine Therapy in Oncology Drug Pipeline Update 2014 Cytokine Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Cytokine Therapy in Oncology Drug Pipeline Update 2014

There are today 81 companies plus partners developing 105 cytokine drugs in 217 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs...

July 2014
FROM
Cellular Therapy in Oncology Drug Pipeline Update 2014 Cellular Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Cellular Therapy in Oncology Drug Pipeline Update 2014

There are today 84 companies plus partners developing 96 cellular therapy drugs in 191 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased...

July 2014
FROM
Angiogenesis in Oncology Drug Pipeline Update 2014 Angiogenesis in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Angiogenesis in Oncology Drug Pipeline Update 2014

There are today 305 companies plus partners developing 376 angiogenesis drugs in 1674 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased...

July 2014
FROM
Biologicals in Oncology Drug Pipeline Update 2014 Biologicals in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Biologicals in Oncology Drug Pipeline Update 2014

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1686...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos